Circulating lipocalin-2 and features of metabolic syndrome in community-dwelling older women: A cross-sectional study

• Published in: Bone (New York, N.Y.) N.Y.), 2023-11, Vol.176, p.116861-116861, Article 116861
• Main Authors: Bauer, Carlie, Sim, Marc, Prince, Richard L., Zhu, Kun, Lim, Ee M., Byrnes, Elizabeth, Pavlos, Nathan, Lim, Wai H., Wong, Germaine, Lewis, Joshua R., Levinger, Itamar
• Format: Article
• Language: English
• Subjects: Aging; Bone-muscle-fat interactions; Human association studies; Metabolism
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/j.bone.2023.116861

Lipocalin-2 (LCN2) is released by several cell types including osteoblasts and adipocytes and has been suggested as a marker of renal dysfunction, metabolic syndrome (MetS) and type 2 diabetes (T2D). Whether LCN2 is linked to these diseases in older women remains unknown. This study investigated whether LCN2 is related to features of MetS and T2D in older women. This cross-sectional study included 705 non-diabetic women (mean age 75.1 ± 2.6 years) for MetS analysis and 76 women (mean age 75.4 ± 2.8 years) with T2D. Total circulating LCN2 levels were analysed using a two-step chemiluminescent microparticle monoclonal immunoassay. MetS was determined by a modified National Cholesterol Education Program Adult Treatment Panel III classification. Multivariable-adjusted logistic regression analysis was used to assess odds ratios between LCN2 quartiles and MetS. Women in the highest LCN2 quartile had approximately 3 times greater risk for MetS compared to women in the lowest quartile (OR 3.05; 95%CI 1.86–5.02). Women with T2D or MetS scores of ≥ 3 had higher LCN2 levels compared to women with a MetS score of 0 (p